Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine

Behavioural Pharmacology

Volumn 8, Issue 2-3, 1997, Pages 223-235

  Tomkins, D M ^a   Otton, S V ^b   Joharchi, N ^b   Berns, T ^b   Wu, D ^b   Corrigall, W A ^b   Sellers, E M ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

Amphetamine; Budipine; Drug discrimination; Hyperactivity; Quinine; Rat; Self administration

Indexed keywords

BUDIPINE; COCAINE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DEXAMPHETAMINE; DRUG METABOLITE; HYDROXYAMPHETAMINE; QUININE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISCRIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELF ADMINISTRATION; ENZYME DEFICIENCY; ENZYME INHIBITION; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; STIMULUS GENERALIZATION;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROAMPHETAMINE; DISCRIMINATION (PSYCHOLOGY); DRUG INTERACTIONS; ENZYME INHIBITORS; GENERALIZATION, STIMULUS; MALE; MOTOR ACTIVITY; P-HYDROXYAMPHETAMINE; PIPERIDINES; QUININE; RATS; RATS, WISTAR; SELF ADMINISTRATION;

EID: 0030872726     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Agon P, Braeckman R, van Haver D, Denutte H, Geopethals P, Donche H, Vermullen F, Deman J and Kaufman J-M (1988) Drug distribution in dog brain studied by positron emission tomography. Biopharmaceutics Drug Disposition, 9, 567-577.
2. Al-Dabbagh SG, Idle JR and Smith RL (1981) Animal modelling of human polymorphic drug oxidation: the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology, 33, 161-164.
3. Barham HM, Lennard MS and Tucker GT (1994) An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochemical Pharmacology, 47, 1295-1307.
4. Brosen K, Otton SV and Gram LF (1986) Imipramine demethylation and hydroxylation, impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics, 40, 543-549.
5. Burde RM and Thompson HS (1991) Hydroxyamphetamine: a good drug lost? American Journal of Ophthalmology, 111, 100-102.
6. Chen ZR, Bochner F, Somogyi A and Irvine RJ (1990) Codeine O-demethylation in the rat: interspecies variability and inhibition by quinidine and dextromethorphan. Clinical and Experimental Pharmacy and Physiology, Suppl 16, Abstract 150.
7. Cheung SW, Nolte H, Otton SV, Tyndale RF, Wu PH and Sellers EM (1997) Simultaneous determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. Journal of Chromatography, 690, 77-87.
8. Cleary J, Mikus G, Simogyi A and Bochner F (1994) The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley Dark Agouti rat model. Journal of Pharmacology and Experimental Therapeutics, 271, 1528-1534.
9. Colpaert FC, Kuyps J, Niemegeers C and Janssen P (1976) Discriminative stimulus properties of a low dl-amphetamine dose. Archives Internationales de Pharmacodynamie et de Therapie, 223, 34-42.
10. de Saint Hilaire Z, Python A, Blanc G, Charnay Y and Gaillard JM (1995) Effects of WIN 35,428 a potent antagonist of dopamine transporter on sleep and locomotor activity in rats. Neuroreport, 6, 2182-2186.
11. Desmeules J, Dayer P, Gascon MP and Magistris M (1991) Impact of genetic and environmental factors on codeine analgesia. European Journal of Clinical Pharmacology, 41, 23-26.
12. Dring LG, Smith RL and William RT (1970) The metabolic fate of amphetamine in man and other species. Biochemical Journal, 116, 425-435.
13. Eichelhaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: Clinical aspects. Pharmacology and Therapeutics, 46, 377-394.
14. Fonne-Pfistrer P, Bargetzi MJ and Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI. P450db1) catalyzing dcbrisoquine 4-hydroxylation. Biochemistry Biophysics Research Communication, 148, 1144-1150.
15. Fray PJ, Sahakian BJ, Robbins TW, Koob GF and Iversen SD (1980) An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology, 69, 253-259.
16. Freeman JJ and Sulser F (1974) Formation of p-hydroxynorephedrine in brain following intraventricular administration of p-hydroxyamphetamine. Neuropharmacology, 13, 1187-1190.
17. Higgins GA, Joharchi N, Wang Y, Corrigall WA and Sellers EM (1994a) The CCK(A) antagonist devazepide does not modify opioid self administration or drug discrimination: comparison with the dopamine antagonist haloperidol. Brain Research, 640, 246-254.
18. Higgins GA, Sills TL, Tomkins DM, Sellers EM and Vaccarino FJ (1994b) Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion. Pharmacology Biochemistry and Behavior, 48, 1019-1024.
19. Hooks MS, Jones DNC, Justice JB and Holtzman SG (1992) Naloxone reduces amphetamine-induced stimulation of locomotor activity and in vivo dopamine release in the striatum and nucleus accumbens. Pharmacology Biochemistry and Behavior, 42, 765-770.
20. Hooks MS, Jones DN, Holtzman SG, Juncos JL, Kaliva PW and Justice JB Jr. (1994) Individual differences in behaviour following amphetamine, GBR-12909, or apomorphine but not SKF or quinpirole. Psychopharmacology, 116, 217-225.
21. Huang J-T and Ho BT (1974) Discriminative stimulus properties of d-amphetamine and related compounds in rats. Pharmacology Biochemistry and Behavior, 2, 669-673.
22. Jackisch R, Huang HY, Reimann W and Limberger M (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. Journal of Pharmacology and Experimental Therapeutics, 264, 889-898.
23. Jones CN, Hill HF and Harris RT (1974) Discriminative response control by d-amphetamine and related compounds in the rat. Psychopharmacologia, 36, 347-356.
24. Jones CN, Grant LD and Vospalek DM (1976) Temporal parameters of d-amphetamine as a discriminative stimulus in the rat. Psychopharmacologia, 46, 59-64.
25. Kobayashi S, Murray S, Watson D, Sesardic D, Davis DS and Boobis AR (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochemical Pharmacology, 38, 2795-2799.
26. Kroemer HK and Eichelbaum M (1995) Molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sciences, 56, 2285-2298.
27. Law MYL and Moody DE (1994) Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague Dawley and Dark Agouti rats. Life Sciences, 54, 1073-1079.
28. Liccione JJ and Maines MD (1989) Manganese-mediated increase in the rat brain mitochondrial cytochrome P-450 and drug metabolism activity: susceptibility of the striatum. Journal of Pharmacology and Experimental Therapeutics, 248, 222-228.
29. Lin LY, Kumagai Y and Cho AK (1992) Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain micro-somes. Chemical Research in Toxicology, 5, 401-406.
30. Mansbach RS and Balster RL (1993) Effects of mazindol on behaviour maintained or occasioned by cocaine. Drug and Alcohol Dependence, 32. 183-192.
31. McKenna ML and Ho BT (1980) The role of dopamine in the discriminative stimulus properties of cocaine. Neuropharmacology, 19, 297-303.
32. Mikus G, Somogyi AA, Bochner F and Eichelbaum M (1990) Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochemical Pharmacology, 41, 757-762.
33. Miller KW, Freeman JJ, Dingell JV and Sulser F (1970) On the mechanisms of amphetamine potentiation by iprindole. Experientia, 26, 863-864.
34. Moody DE, Ruangyuttikarn W and Law MY (1990) Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. Journal of Analytical Toxicology, 14, 311-317.
35. Ritchie R, Chen ZR, Somogyi AA and Bochner F (1990) Brain O-demethylation of codeine to morphine and analgesia in a rat model. Clinical and Experimental Pharmacy and Physiology, Suppl 16, Abstract 151.
36. Schenk S, Robinson B and Amit Z (1988) Housing conditions fail to affect the intravenous self-administration of amphetamine. Pharmacology Bioehemistry and Behavior, 31, 59-62.
37. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR and Gram LF (1990) Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clinical Pharmacology, and Therapeutics, 48, 686-693.
38. Stolerman IP and D'Mello GD (1981) Role of training conditions in discrimination of central nervous system stimulants by rats. Psychopharmacology, 73, 295-303.
39. Sulser F, Owens LM and Dingell JV (1966) On the mechanism of amphetamine potentiation by desipramine (DMI). Life Sciences, 5, 2005-2010.
40. Suzuki T, Chiang H-JF, Yanaura S, Yoshida T and Kuroiwa Y (1984) Enhancement of behavioral effect and acute toxicity of methamphetamine by quinine in rats. Japanese Journal of Pharmacology, 35, 273-277.
41. Suzuki T, Chiang H-JF, Yanaura S, Yoshida T and Kuroiwa Y (1986) Studies on the mechanism of interaction between methamphetamine and quinine in rats. Journal of Pharmacobio-Dynamics, 9, 234-238.
42. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ and Niznik HB (1991) Neuronal cytochrome P450IID1 (debrisoquine/sparteine type): potent inhibition of activity by ( - ) cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology, 40, 63-68.
43. Weiss F, Tanzer DJ and Ettenberg A (1988) Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intraaccumbens injections in rats. Pharmacology Biochemistry and Behavior, 30, 309-317.
44. Wu D, Otton SV, Morrow PM, Inaba T, Kalow W and Sellers EM (1993) Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715-719.
45. Yokel RA and Pickens R (1974) Drug level of d- and 1-amphetamine during intravenous self-administration. Psychopharmacologia, 34, 255-264.
46. Yokel RA and Wise RA (1976) Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology, 48, 311-318.
47. Zysset T, Zeugin T and Kupfer A (1988) In vivo and in vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochemical Pharmacology, 37, 3155-3160.